Gotowa bibliografia na temat „Clozapine”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Clozapine”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Clozapine"
Pardis, Parnian, Gary Remington, Roshni Panda, Milan Lemez i Ofer Agid. "Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review". Journal of Psychopharmacology 33, nr 10 (26.07.2019): 1187–98. http://dx.doi.org/10.1177/0269881119862535.
Pełny tekst źródłaCoward, D. M. "General Pharmacology of Clozapine". British Journal of Psychiatry 160, S17 (maj 1992): 5–11. http://dx.doi.org/10.1192/s0007125000296840.
Pełny tekst źródłaLieberman, Jeffrey A., Bruce L. Saltz, Celeste A. Johns, Simcha Pollack, Michael Borenstein i John Kane. "The Effects of Clozapine on Tardive Dyskinesia". British Journal of Psychiatry 158, nr 4 (kwiecień 1991): 503–10. http://dx.doi.org/10.1192/bjp.158.4.503.
Pełny tekst źródłaRajkumar, Anto P., B. Poonkuzhali, Anju Kuruvilla, Alok Srivastava, Molly Jacob i K. S. Jacob. "Association betweenCYP1A2gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia". Acta Neuropsychiatrica 25, nr 1 (luty 2013): 2–11. http://dx.doi.org/10.1111/j.1601-5215.2012.00638.x.
Pełny tekst źródłaOliveira-Souza, Ricardo de, Rogério Paysano Marrocos i Jorge Moll. "Clozapine for severe ("kraepelinian") schizophrenia: Sustained improvement over 5 years". Dementia & Neuropsychologia 2, nr 1 (marzec 2008): 71–75. http://dx.doi.org/10.1590/s1980-57642009dn20100014.
Pełny tekst źródłaOrejas, O., C. Masferrer Herrera, C. Macías Castellví i P. Flores Martínez. "Subacute psychiatric hospitalization unit: The role of clozapine". European Psychiatry 33, S1 (marzec 2016): S548—S549. http://dx.doi.org/10.1016/j.eurpsy.2016.01.2026.
Pełny tekst źródłaStanton, Robert J., Chris Paxos, Werner J. Geldenhuys, B. Pharm, Jessica L. Boss, Mark Munetz, Altaf S. Darvesh i M. Pharm. "Clozapine underutilization in treatment-resistant schizophrenia". Mental Health Clinician 5, nr 2 (1.03.2015): 63–67. http://dx.doi.org/10.9740/mhc.2015.03.063.
Pełny tekst źródłaFehsel, K., K. Schwanke, BA Kappel, E. Fahimi, E. Meisenzahl-Lechner, C. Esser, K. Hemmrich, T. Haarmann-Stemmann, G. Kojda i C. Lange-Asschenfeldt. "Activation of the aryl hydrocarbon receptor by clozapine induces preadipocyte differentiation and contributes to endothelial dysfunction". Journal of Psychopharmacology 36, nr 2 (3.01.2022): 191–201. http://dx.doi.org/10.1177/02698811211055811.
Pełny tekst źródłaDavis, Erica A. K., i Deanna L. Kelly. "Clozapine-associated renal failure: A case report and literature review". Mental Health Clinician 9, nr 3 (1.05.2019): 124–27. http://dx.doi.org/10.9740/mhc.2019.05.124.
Pełny tekst źródłaJalenques, Isabelle, i André-Julien Coudert. "Clozapine for the treatment of levodopa-induced psychosis and dyskinesia in Parkinson's disease". Irish Journal of Psychological Medicine 11, nr 2 (czerwiec 1994): 83–88. http://dx.doi.org/10.1017/s0790966700012404.
Pełny tekst źródłaRozprawy doktorskie na temat "Clozapine"
Fisher, Michael. "Clozapine-induced paroxysmal discharges". Thesis, University of Newcastle upon Tyne, 2013. http://hdl.handle.net/10443/2190.
Pełny tekst źródłaMourlot-Chabanon, Pascale. "Bilan d'utilisation de la clozapine". Montpellier 1, 1997. http://www.theses.fr/1997MON11031.
Pełny tekst źródłaDAHER, OSCAR. "Tolerance a la clozapine (leponex*)". Saint-Etienne, 1993. http://www.theses.fr/1993STET6205.
Pełny tekst źródłaDurão, Ana Maria Sertori. ""Grupo de acompanhamento de pacientes e familiares de portadores de esquizofrenia medicados com clozapina: o impacto sobre o cotidiano de suas vidas"". Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/22/22131/tde-08092004-165526/.
Pełny tekst źródłaThis descriptive, exploratory, assessment study of a qualitative nature has as its aim, to describe the daily life of the schizophrenic sufferer in three moments: before the use of clozapine; after clozapine use and after clozapine use and group follow-up. The population was made up of all the schizophrenia sufferers using clozapine and the most frequently accompanying relative that participated in the atypical medication group (GRUMA).Data was collected through tape recorded, semi structured interviews with patients and relatives using a previously prepared guideline. Afterwards the recorded interview was hand written by the researcher and a qualitative analysis based on the steps proposed by Minayo (1996) was carried out. The results obtained, showed that before the use of clozapine and group followup, unpredictable behaviour and overt aggressiveness were constant in the daily lives of the patients and their families, causing, in both, great psychological suffering as well as lack of know ledge about the disease. The manifestation of symptoms constituted cause for isolation, loss of relationships with close people affecting in a significant manner work, study and social living. After the use of clozapine, before beginning the folowup group, the patients presented expressive improvement of the positive and negative symptoms of the disease, principally in as far as agressiveness was concerned. However, it was found that the difficulties continued in relationships at work, in study pursuits, in social living activities as well as in the patients other daily talks. It was possible to verify that after the use of clozapine with the support of the followup group, there was an improvement in relationships that were difficult before, reduction of anxiety and agressiveness, thus increasing self respect, tolerance, willpower, as well as, the strenghthening of family ties. The group in question allowed the patients and relatives to be guided to recognize the symptoms of the disease and the previous signs of the collateral effects of the treatment. The importance of acceptance, of friendship and the comfort encountered in the group was also verified, as well as solidarity and security. It was also ascertained that inspite of the adversities of the still incipient health system, professionals still seem to invest in the possibilities of finding, looking for and of creating new realities in the daily lives of patients and their families.
Wilkes, Susanna Jane Lawson. "An investigation into clozapine induced agranulocytosis". Thesis, University College London (University of London), 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.336629.
Pełny tekst źródłaTschen, Alice C. "The in vitro metabolism of clozapine, implications for an in vitro predictive test for clozapine-induced agranulocytosis". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp03/MQ28678.pdf.
Pełny tekst źródłaHsu, Pei-Chun (Lisa). "Capillary electrophoresis improving clinical measurement of clozapine". Thesis, University of Canterbury. School of Biological Sciences, 2008. http://hdl.handle.net/10092/2260.
Pełny tekst źródłaSalmi, Peter. "Clozapine as a dopamine D1 receptor agonist /". Stockolm : Universitet Stockholms, 1998. http://catalogue.bnf.fr/ark:/12148/cb401175060.
Pełny tekst źródłaRaaska, Kari. "Pharmacokinetic interactions of clozapine in hospitalized patients". Helsinki : University of Helsinki, 2003. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/raaska/.
Pełny tekst źródłaJolivel, Céline. "Etude médico-économique de la clozapine (Leponex (R)), neuroleptique atypique, dans le traitement des schizophrénies résistantes". Bordeaux 2, 1997. http://www.theses.fr/1997BOR2P054.
Pełny tekst źródłaKsiążki na temat "Clozapine"
Bleakley, Stephen. Clozapine handbook. Dorsington: Lloyd-Reinhold Communications, 2013.
Znajdź pełny tekst źródła1941-, Jones Barry, Lapierre Yvon D, Canadian Psychiatric Association Meeting, Royal Society of Medicine Services (Great Britain) i Sandoz Canada, red. Clozapine in treatment-resistant schizophrenia: A scientific update. London: Royal Society of Medicine Services, 1992.
Znajdź pełny tekst źródłaY, Meltzer Herbert, red. Clozapine: A 5-year perspective and clinical recommendations. Memphis, TN: Physicians Postgraduate Press, 1996.
Znajdź pełny tekst źródłaGlennie, Judith. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa, Ont: Canadian Coordinating Office for Health Technology Assessment, 1997.
Znajdź pełny tekst źródłaMasellis, Mario. Pharmacogenetic analysis of serotonin receptors and clinical response to clozapine in schizophrenia patients. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1999.
Znajdź pełny tekst źródłaDegen, Kathleen. Return from madness: Psychotherapy with people taking the new anti-psychotic medications and emerging from severe, lifelong, and disabling schizophrenia. Northvale, N.J: Aronson, 1996.
Znajdź pełny tekst źródłaNaber, D., F. Müller-Spahn i F. G. Pajonk, red. Clozapin. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60551-2.
Pełny tekst źródłaTherapy-resistant schizophrenia. Basel: Karger, 2010.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust, Monopolies, and Business Rights. Marketing of Clozaril: Improved safety or barrier to access : hearing before the Subcommittee on Antitrust, Monopolies and Business Rights of the Committee on the Judiciary, United States Senate, One Hundred Second Congress, first session, on the marketing of Clozaril, a drug for the treatment of schizophrenia, March 5, 1991. Washington: U.S. G.P.O., 1991.
Znajdź pełny tekst źródłaNaber, Dieter, i Franz Müller-Spahn, red. Clozapin Pharmakologie und Klinik eines atypischen Neuroleptikums. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-93547-3.
Pełny tekst źródłaCzęści książek na temat "Clozapine"
Courtney, John C., i Cristy Akins. "Clozapine". W Encyclopedia of Clinical Neuropsychology, 605. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-79948-3_1643.
Pełny tekst źródłaCourtney, John C., Cristy Akins i Gonzalez Efrain. "Clozapine". W Encyclopedia of Clinical Neuropsychology, 1–2. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56782-2_1643-2.
Pełny tekst źródłaCourtney, John C., Cristy Akins i Efrain Antonio Gonzalez. "Clozapine". W Encyclopedia of Clinical Neuropsychology, 827. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_1643.
Pełny tekst źródłaHoyer, Daniel, Eric P. Zorrilla, Pietro Cottone, Sarah Parylak, Micaela Morelli, Nicola Simola, Nicola Simola i in. "Clozapine". W Encyclopedia of Psychopharmacology, 305. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1621.
Pełny tekst źródłaYoung, Stephanie, i Noreen Jakeman. "Clozapine". W Psychiatry: Breaking the ICE, 235–41. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118557211.ch37.
Pełny tekst źródłaFreudenreich, Oliver. "Clozapine". W Psychotic Disorders, 231–48. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-29450-2_17.
Pełny tekst źródłaMcDougle, Christopher J., i Carolyn A. Doyle. "Clozapine". W Encyclopedia of Autism Spectrum Disorders, 671–72. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1698-3_822.
Pełny tekst źródłade Groot, Anton C. "Clozapine". W Monographs In Contact Allergy, 329. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003158004-154.
Pełny tekst źródłaMcDougle, Christopher J., i Carolyn A. Doyle. "Clozapine". W Encyclopedia of Autism Spectrum Disorders, 999–1000. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-319-91280-6_822.
Pełny tekst źródłaBrown, Julia E. H. "Clozapine frames". W The Clozapine Clinic, 147–51. London: Routledge, 2022. http://dx.doi.org/10.4324/9781003018087-24.
Pełny tekst źródłaStreszczenia konferencji na temat "Clozapine"
arias, sixto A., Jeffrey S. kwon i Paul Cohen. "Clozapine-Induced Lymphocytic Alveolitis". W American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5666.
Pełny tekst źródłaHua Chong, Dr Jun, i Dr Franz Eversheim. "Clozapine-induced reversible Brugada Syndrome". W Annual International Conferences on Cardiology & Cardiovascular Medicine Research. Global Science & Technology Forum (GSTF), 2014. http://dx.doi.org/10.5176/2382-5669_ccmr14.15.
Pełny tekst źródła"O-008 - CLOZAPINE TREATMENT AND ACUTE RELAPSE'S PREVENTION IN DUAL DIAGNOSIS PATIENTS". W 24 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE PATOLOGÍA DUAL. SEPD, 2022. http://dx.doi.org/10.17579/abstractbooksepd2022.o008.
Pełny tekst źródłaChane-Kene, A., F. Plassart, O. Chauvel, C. Lamisse i JL Pons. "4CPS-174 A new breath for clozapine …". W 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.323.
Pełny tekst źródłaGupta, K., D. Mohan i A. Agarwal. "Clozapine Induced Hypothermia: A Chilling Side Effect". W American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4820.
Pełny tekst źródłaRomanova, Olga, Dmitry Sundukov, Arkady Golubev i Mikhail Blagonravov. "Forensic evaluation of the rate of development of ARDS in cases of poisoning with clozapine and baclofen". W Issues of determining the severity of harm caused to human health as a result of the impact of a biological factor. ru: Publishing Center RIOR, 2020. http://dx.doi.org/10.29039/conferencearticle_5fdcb03aabda96.57249908.
Pełny tekst źródła"CLOZAPINA Y TABAQUISMO: RIESGO DE INTOXICACIÓN FARMACOLÓGICA EN EL PACIENTE FUMADOR EN TRATAMIENTO CON CLOZAPINA AL ABANDONAR EL HÁBITO TABÁQUICO". W 23° Congreso de la Sociedad Española de Patología Dual (SEPD) 2021. SEPD, 2021. http://dx.doi.org/10.17579/sepd2021p033s.
Pełny tekst źródłaClement, H., A. Meyer, L. Böhm, J. Böckmann, C. Geffert, C. Fleischhaker i E. Schulz. "Oral fluid venlafaxine and clozapine levels for therapeutic drug monitoring". W Abstracts of the 1st Symposium of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) and Deutsche Gesellschaft für Biologische Psychiatrie (DGBP). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679173.
Pełny tekst źródłaBen-Yoav, H., T. E. Winkler, S. E. Chocron, S. M. Restaino, G. R. Costa, E. Kim, D. L. Kelly, G. F. Payne i R. Ghodssi. "Bio-amplifying lab-on-a-chip for antipsychotic clozapine treatment monitoring". W 2013 Transducers & Eurosensors XXVII: The 17th International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS & EUROSENSORS XXVII). IEEE, 2013. http://dx.doi.org/10.1109/transducers.2013.6626766.
Pełny tekst źródłaKuzin, M., G. Schoretsanitis, E. Haen, C. Hiemke, G. Gründer i M. Paulzen. "The clinical relevance of the pharmacological interaction between clozapine and sertraline". W Abstracts of the 1st Symposium of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) and Deutsche Gesellschaft für Biologische Psychiatrie (DGBP). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679178.
Pełny tekst źródłaRaporty organizacyjne na temat "Clozapine"
Merino, Diane, Arnaud Fernandez, Alexandre Gérard, Nouha Ben Othman, Fanny Rocher, Florence Askenazy, Céline Verstuyft, Milou-Daniel Drici i Susanne Thümmler. Protocol: Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, maj 2022. http://dx.doi.org/10.37766/inplasy2022.5.0025.
Pełny tekst źródłaMetformin shows early promise for controlling clozapine-related weight gain. National Institute for Health Research, sierpień 2016. http://dx.doi.org/10.3310/signal-000293.
Pełny tekst źródłaUncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia. National Institute for Health Research, listopad 2017. http://dx.doi.org/10.3310/signal-000504.
Pełny tekst źródła